Galderma Patient Services for Nemluvio

Your patient’s real-time navigation partner to help guide them to success

GPS (Galderma Patient Services) for NEMLUVIO™ helps patients start and stay on treatment by helping to navigate coverage and providing access to assistance programs and adherence support.

Go To Hub 

Get NEMLUVIO fast

  1. Complete Enrollment Form with patient consent

      Enrollment Form

  2. Send the completed enrollment form to the in-network specialty pharmacy (SP) of choice or Hub

      Specialty Pharmacy Fact Sheet

  3. Confirm eligibility and patient receives NEMLUVIO right to their door*

Start therapy

Quick Start

Provides first/loading dose of NEMLUVIO at no cost for eligible patients whose treatment is impacted by a delay in coverage.

Note: Be sure to fill out the Free Goods Rx within the Enrollment Form to make sure your patients can get started quickly.

Patient Welcome Kit

This helpful kit is sent directly to patients that opted in during enrollment. It includes starter materials, Galderma Skincare Cetaphil® samples, and an overview of key GPS for NEMLUVIO support programs.

Patient Assistance Program

Helps patients who financially qualify gain access to treatment when they don't have coverage or have insufficient/limited coverage for NEMLUVIO.

Nurse Navigator Support

Nurse Navigators are available online, over-the-phone, or in person to provide live injection training, injection assistance, and ongoing disease management support to your patients.

Note: While filling out the Enrollment Form, you may sign your patients up for Nurse Navigator support with their consent.

Stay on track

Co-Pay Assistance

Eligible patients may pay as little as $0†

The Co-Pay program helps commercially insured patients reduce or eliminate out-of-pocket costs and improve affordability.

Replacement Product Program

Offers replacement dose(s) of NEMLUVIO due to product defect or error during administration.

Bridge

Prevents a gap in treatment for eligible patients who have a temporary loss of insurance coverage.

Sharps Disposal Program

Ensures that patients who prefer a convenient mail-back option can properly dispose of NEMLUVIO self-injectable pens.

katherine

Get your patients started with NEMLUVIO

Visit the Hub or call 1-855-NEMLUVIO to contact a Field Access Manager to see if your patient may be eligible for any GPS for NEMLUVIO programs

GO TO HUB 

IMPORTANT SAFETY INFORMATION

INDICATION: NEMLUVIO® (nemolizumab-ilto) is an interleukin-31 receptor antagonist indicated for the treatment of adults with prurigo nodularis.

CONTRAINDICATION: NEMLUVIO is contraindicated in patients with known hypersensitivity to nemolizumab-ilto or to any of the excipients in NEMLUVIO.

WARNINGS AND PRECAUTIONS:
Hypersensitivity reactions have been reported with NEMLUVIO use. If clinically significant hypersensitivity reaction occurs, immediately institute appropriate therapy, and discontinue NEMLUVIO. Avoid use of live vaccines during treatment with NEMLUVIO.

ADVERSE REACTIONS:
Most common adverse reactions (incidence ≥1%) are headache, dermatitis atopic, eczema, and eczema nummular.

USE IN SPECIFIC POPULATIONS:
Pregnancy: There are no adequate and well-controlled studies on NEMLUVIO in pregnant women. The limited available information on NEMLUVIO use during pregnancy is not sufficient to inform a drug-associated risk of major birth defects or miscarriage in humans. Human IgG antibodies are known to cross the placental barrier; therefore, NEMLUVIO may be transmitted from the mother to the developing fetus.

Lactation: There are no data on the presence or transfer of NEMLUVIO in human milk, the effects on the breastfed infant, or the effects on milk production. Human IgG is known to be present in human milk. The effects of local gastrointestinal and limited systemic exposure to NEMLUVIO on the breastfed infant are unknown. NEMLUVIO has not been administered to nursing/lactating women. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for NEMLUVIO and any potential adverse effects on the breastfed child from NEMLUVIO or from the underlying maternal condition.

Please see full Prescribing Information, including Patient Information.